Score Overview
Explore the 2021 public Archive ranking →
Where Jazz Pharmaceuticals PLC has ranked, year by year
Showing all available years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- JAZZ
2012: 50.0% · 2021: 28.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 231.52 | — |
1 Year2025-09-30 | $ 131.80 | 75.66% |
5 Years2021-09-30 | $ 130.21 | 77.81% |
10 Years2016-09-30 | $ 121.48 | 90.58% |
All Time2007-06-01 | $ 17.73 | 13x |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | All Time2007-06-01 |
|---|---|---|---|---|---|
| Price | $ 231.52 | $ 131.80 | $ 130.21 | $ 121.48 | $ 17.73 |
| Return | — | 75.66% | 77.81% | 90.58% | 13x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 4.60B | $ 940M | $ 2.19B |
| 2025 | $ 4.26B | -$ 356M | $ 2.44B |
| 2024 | $ 4.06B | $ 560M | $ 2.99B |
| 2023 | $ 3.83B | $ 414M | $ 1.62B |
| 2022 | $ 3.65B | -$ 224M | $ 881M |
| 2021 | $ 3.09B | -$ 328M | $ 591M |
| 2020 | $ 2.36B | $ 238M | $ 2.13B |
| 2019 | $ 2.16B | $ 523M | $ 1.07B |
| 2018 | $ 1.89B | $ 447M | $ 824M |
| 2017 | $ 1.61B | $ 487M | $ 601M |
| 2016 | $ 1.48B | $ 396M | $ 425M |
| 2015 | $ 1.32B | $ 329M | $ 988M |
| 2014 | $ 1.17B | $ 58M | $ 684M |
| 2013 | $ 872M | $ 216M | $ 636M |
| 2012 | $ 585M | $ 288M | $ 387M |
| 2011 | $ 272M | $ 124M | $ 157M |
| 2010 | $ 173M | $ 32M | $ 44M |
| 2009 | $ 128M | -$ 6M | $ 15M |
| 2008 | $ 67M | -$ 184M | $ 25M |
| IPO2007 | $ 65M | -$ 138M | $ 102M |
Jazz Pharmaceuticals PLC fundamental performance
Between 2020 and 2025, revenue grew from $ 2.36B to $ 4.26B and net income went from $ 238M to -$ 356M. Revenue increased in every one of those 5 years; net income in 4.
Across Jazz Pharmaceuticals PLC's full reported history, from 2007 to 2025, revenue grew from $ 65M to $ 4.26B and net income went from -$ 138M to -$ 356M. Revenue increased in 100% of the years measured; net income in 63%.
Jazz Pharmaceuticals PLC currently holds a 5-year HDB Score of 8.4 out of 10. How the HDB Score is calculated.
Membership
Continue JAZZ’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
